The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix (R) and Epaxal (R)) in Korean Young Adults
- Authors
- Lim, Jiseun; Song, Yeong-Juh; Park, Woong-Sub; Sohn, Haesook; Lee, Moo-Sik; Shin, Dong-Hoon; Kim, Chun-Be; Kim, Hwasung; Oh, Gyung-Jae; Ki, Moran
- Issue Date
- 1-Jan-2014
- Publisher
- 연세대학교의과대학
- Keywords
- Hepatitis A virus; hepatitis A vaccine; immune; vaccine; young adults
- Citation
- Yonsei Medical Journal, v.55, no.1, pp 126 - 131
- Pages
- 6
- Journal Title
- Yonsei Medical Journal
- Volume
- 55
- Number
- 1
- Start Page
- 126
- End Page
- 131
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/12526
- DOI
- 10.3349/ymj.2014.55.1.126
- ISSN
- 0513-5796
1976-2437
- Abstract
- Purpose: Assessing the immunogenicity of a single dose of hepatitis A virus (HAV) vaccines is important because some people receive only a single dose. However, previous studies have shown variable results and have not examined the effects of demographic characteristics other than gender. This study was performed to examine the immunogenicity of a single dose of HAV vaccine according to the vaccine type and demographic characteristics in young adults. Materials and Methods: Seronegative medical school students were randomly allocated to receive either Havrix or Epaxal. Results: After approximately 11 months, the seroconversion rate in 451 participants was 80.7%. In men, the Havrix group showed a significantly higher seroconversion rate (81.9%) than the Epaxal group (69.2%), whereas both vaccine groups showed similarly high immunogenicity in women (Havrix: 90.1%, Epaxal: 92.9%; P for interaction=0.062). According to the results of a multivariate analysis, Epaxal showed significantly lower immunogenicity than Havrix only in men. Age, obesity, drinking, smoking, and follow-up time did not significantly affect seroconversion in either gender. Conclusion: The seroconversion rate of single-dose HAV vaccines was low in men, particularly in those who received Epaxal. Our results suggest that gender effects should be considered when comparing the immunogenicity of different HAV vaccines.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Preventive Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/12526)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.